Company Verici Dx plc

Equities

VRCI

GB00BM8HZD43

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. Other stock markets 16:35:07 06/03/2026 GMT			5-day change	1st Jan Change
0.5750 ^GBX	0.00%		-2.54%	-20.69%

02-05	EARNINGS AND TRADING: React sales increase; Arcontech profit declines	AN
02-05	Verici Dx's Tutivia Added as In-network Test Under BCBS Deal	MT

Business description: Verici Dx plc

Verici Dx plc is an immuno-diagnostics development company. The Company develops a suite of tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. Its products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including subclinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. Its subsidiary is Verici Dx Inc.

Number of employees: 15

Sales by Activity: Verici Dx plc

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Development of Prognostic and Diagnostic Tests for Kidney Transplant Patients	-	-	-	1.01M	3.34M

See all business segments

Geographical breakdown of sales: Verici Dx plc

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)

See all geographic segments

Executive Committee: Verici Dx plc

Manager	Title	Age	Since
Sara Barrington CEO	Chief Executive Officer	59	18/08/2020
David Anderson DFI	Director of Finance/CFO	63	-

See VERICI DX PLC governance

Composition of the Board of Directors: Verici Dx plc

Director	Title	Age	Since
Julian Baines CHM	Chairman	61	-
Aubrey Powell BRD	Director/Board Member	-	05/10/2025
Ian Carruthers BRD	Director/Board Member	75	18/08/2020
James McCullough BRD	Director/Board Member	58	21/04/2020
Sara Barrington BRD	Director/Board Member	59	18/08/2020
Lorenzo Gallon BRD	Director/Board Member	61	18/08/2021

Composition of the Board of Directors

Shareholders: Verici Dx plc

Name	Equities	%	Valuation
Puma Investment Management Ltd. 10.46 %	158,300,000	10.46 %	2 M p
Canaccord Genuity Wealth Ltd. 9.991 %	151,212,458	9.991 %	2 M p
Unicorn Asset Management Ltd. 7.903 %	119,619,325	7.903 %	1 M p
UBS Asset Management (UK) Ltd. 7.817 %	118,314,708	7.817 %	1 M p
The Mount Sinai Hospital 1.288 %	19,501,330	1.288 %	194 038 p

List of VERICI DX PLC shareholders

Company details: Verici Dx plc

Verici Dx Plc

393 Nichol Mill Lane

37067, Franklin

https://vericidx.com

Diagnostic & Testing Substances

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
VERICI DX PLC	0.00%	-2.54%	-80.00%	-93.43%	11.65M
BIOMÉRIEUX	+0.16%	-4.60%	-17.26%	+1.04%	13.06B
GUARDANT HEALTH, INC.	-1.49%	-2.88%	+131.94%	+215.79%	11.96B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+4.83%	+4.11%	-9.89%	-5.27%	6.21B
CARIS LIFE SCIENCES, INC.	-3.28%	-7.70%	-	-	5.25B
LANTHEUS HOLDINGS, INC.	-4.91%	-3.14%	-31.77%	-3.56%	4.69B
DIASORIN S.P.A.	0.00%	-3.15%	-28.48%	-39.96%	4.31B
ANDON HEALTH CO., LTD.	-2.45%	+10.48%	+16.35%	+1.47%	2.99B
AUTOBIO DIAGNOSTICS CO., LTD.	+1.74%	-3.61%	-16.55%	-42.51%	2.9B
10X GENOMICS, INC.	-3.84%	-9.72%	+77.86%	-57.52%	2.66B
Average	-0.92%	-2.77%	+4.69%	-2.66%	5.4B
Weighted average by Cap.	-0.71%	-2.70%	+25.14%	+43.05%